Naslov
Purine analogues increase the risk of lethal and/or prolonged COVID19 while obinutuzumab increases the risk of prolonged but not lethal infection in patients treated for lymphoid malignancies - a study of Krohem, the Croatian group for hematologic diseases

Autori
Aurer, Igor ; Jakšić, Ozren ; Bašić-Kinda, Sandra ; Mrđenović, Stefan ; Ostojić Kolonić, Slobodanka ; Lozić, Dominik ; Holik, Hrvoje ; Novaković Coha, Sabina ; Bernes, Petra ; Krečak, Ivan ; Morić Perić, Martina ; Narančić, Marino ; Mitrović, Zdravko ; Valković, Toni

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Blood, 138 (2021), Suppl 1 / - , 2021, 3553-3553

Skup
63rd ASH Annual Meeting and Exposition

Mjesto i datum
Atlanta (GA), Sjedinjene Američke Države, 11.12.2021. - 14.12.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
purine analogues ; COVID19 ; obinutuzumab ; lymphoid malignancies

Sažetak
Patients with lymphoid malignancies are at increased risk of death due to COVID19. Currently, it is not completely clear whether this is mainly due to disease biology or to anti-lymphoma treatment and whether the prognosis of infection differs in patients treated with different therapies. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is not known whether this risk is affected by the choice of the antibody. To study these questions, KroHem collected data on patients with lymphoid malignancies diagnosed with COVID19 between October 2020 and April 2021. The data presented suggest that the type of anti-lymphoma therapy is, besides age, a main determinant of prognosis of COVID19 in patients with lymphoid malignancies. Use of purine analogues, such as bendamustine and fludarabine, is related to increased risk of lethal and/or prolonged COVID19. These drugs should probably be avoided in patients with indolent NHL and CLL, diseases for whom other effective treatments are available, during the current pandemia. Anti- CD20 monoclonal antibodies seem to have a smaller effect on mortality, with obinutuzumab increasing the risk of prolonged disease, but not of death, in comparison to rituximab.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA